Developing new cancer drugs is expensive. Before a new cancer drug goes to trial it is developed for a year or two, and costs around $100 million. Also, 95% of cancer drugs fail in clinical trials meaning there are lots of misses before a hit. Berg, a biotech startup, wants to harness artificial intelligence to develop the next generation of cancer treatments. The company has created BPM 31510, the first cancer drug developed by artificial intelligence being tested in clinical studies. When cancer spreads mitochondria that usually tell damaged cells to die go crazy, and spread. BPM 31510 focuses on the mitochondria, and tries to restore a normal cell’s dying process. Though BPM 31510 is still in early trial stages, it could hint at how future drugs will be developed.
The next frontier in medicine: drugs designed by artificial intelligence
More of Today's Solutions
Australia’s biggest gun reform in 30 years kicks off this November
BY THE OPTIMIST DAILY EDITORIAL TEAM Eight months after a shooting at a Hanukkah celebration in Bondi Beach killed 15 people, Australia is following ...
Read MoreAre algae oil supplements worth taking? Here’s the evidence
BY THE OPTIMIST DAILY EDITORIAL TEAM There's a pattern in the supplement industry that tends to repeat itself. Researchers find that people who eat ...
Read MoreMeet Jenny, the horse who takes a daily stroll alone through Frankfurt
The following story may not necessarily be a solution, but we hope it puts a smile on your face. In the city of Frankfurt, ...
Read MoreThe grass-eating mystery: why cats and dogs snack on greens
BY THE OPTIMIST DAILY EDITORIAL TEAM You’re out walking your dog or watching your cat in the backyard when, out of nowhere, they start ...
Read More
